0001209191-20-006663.txt : 20200204
0001209191-20-006663.hdr.sgml : 20200204
20200204190323
ACCESSION NUMBER: 0001209191-20-006663
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200131
FILED AS OF DATE: 20200204
DATE AS OF CHANGE: 20200204
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Moriarty John B
CENTRAL INDEX KEY: 0001564621
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35935
FILM NUMBER: 20575670
MAIL ADDRESS:
STREET 1: ALEXION PHARMACEUTICALS
STREET 2: 352 KNOTTER DRIVE
CITY: CHESHIRE
STATE: CT
ZIP: 06410
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PORTOLA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001269021
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 270 EAST GRAND AVENUE, SUITE 22
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-244-6864
MAIL ADDRESS:
STREET 1: 270 EAST GRAND AVENUE, SUITE 22
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-01-31
0
0001269021
PORTOLA PHARMACEUTICALS INC
PTLA
0001564621
Moriarty John B
C/O PORTOLA PHARMACEUTICALS, INC.
270 E. GRAND AVE.
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
EVP, General Counsel
Common Stock
2020-01-31
4
A
0
16250
0.00
A
56728
D
Common Stock
2020-02-03
4
F
0
3544
12.89
D
53184
D
Stock Option (Right to Buy)
12.79
2020-01-31
4
A
0
65000
0.00
A
2030-01-30
Common Stock
65000
65000
D
Grant of Restricted Stock Units ("RSUs") in consideration of services rendered. The RSUs vest in three equal annual installments subject to Reporting Person's Continuous Service under the Issuer's plan documents as of each vest date.
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
The options shall vest as follows: 1/48th of the shares subject to the option shall vest each month after January 31, 2020, subject to the Reporting Person's Continuous Service as of each such date.
/s/ Mike Ouimette, as attorney-in-fact
2020-02-04